Printer Friendly

Chronic Leukemias - Curative Intent Raises the Bar.

DUBLIN, Ireland -- Research and Markets ( has announced the addition of Chronic Leukemias - Curative Intent Raises the Bar to their offering.

Recognizing that prolonging disease-free survival in chronic leukemia relies on the eradication of minimal residual disease has raised the bar for developers of novel pharmacotherapy. In meeting the more demanding success criteria and targeting innovative treatments to cohorts most likely to respond, developers should increasingly employ the use of molecular markers to guide risk stratification.

This report provides an overview of chronic leukemias including epidemiology, etiology, clinical features, staging and prognostic variables. It covers current treatment controversies and novel therapies in the developmental pipeline and provides an analysis of trial data, marketing factors and commercial potential for key technologies in clinical development. The report includes stakeholder opinions and interview transcripts based on qualitative interviews with five opinion leaders from the US and Europe.


Because of the heterogeneity of CLL there is a need to identify biological markers that provide a more robust and reliable prediction of patient outcomes to current and evolving treatment strategies. The identification and application of molecular markers to facilitate prognostication is becoming integral to the treatment decision-making process.

The emergence of Gleevec-resistant CML, reported at rates of 4% with each year of treatment, coupled with only a 50% response rate in patients with advanced disease, indicate the need for novel, efficacious second-line treatment strategies both for patients with Gleevec-resistant chronic phase CML and for virtually all advanced stage patients.

The goal for developers of novel CLL pharmacotherapy is to innovate drug treatments that can salvage patients' refractory to alemtuzumab and improve on the formers toxicity while simultaneously increasing the rate and duration of minimal residual disease negativity.

Reasons to Purchase

--Identify opportunities for more efficacious second-line treatment strategies both for patients with Gleevec-resistant CML and advanced stage patients

--Understand how future advancements in chronic leukemia prognostication have the potential to shift treatment paradigms

--Assess opportunities and challenges facing innovative treatments for chronic leukemias, in particular the drive to eradicate minimal residual disease

For more information visit
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 22, 2005
Previous Article:Lieutenant Governor Kerry Healey to Acknowledge Leading Turkey Donors at the Greater Boston Food Bank.
Next Article:My Little Pony Holiday Film Climbs to Top of Billboard Charts.

Related Articles
Curative Health Services Wins National Telly Award for Diabetes Awareness Month Video News Release.
Curative Health Services Reaches The 1 Million Mark.
Curative Health Services Announces New President and Chief Executive Officer, Paul F. McConnell and New Chief Operating Officer, John C. Prior.
Curative Officers And Directors May Sell Shares To Repay Loans.
Cyclacel Begins Phase I Pharmacologic Study of Oral Sapacitabine in Patients with Advanced Leukemias.
INNOVIVE Pharmaceuticals Enrolls First Patients in Phase I Study of INNO-406 in CML.
Canadians healthier than Americans, health care system credited.
Acesulfame potassium: Soffritti responds.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters